Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) insider Nezam H. Afdhal acquired 2,400 shares of Spring Bank Pharmaceuticals stock in a transaction dated Friday, September 9th. The shares were acquired at an average cost of $12.50 per share, with a total value of $30,000.00. Following the completion of the acquisition, the insider now directly owns 40,150 shares in the company, valued at approximately $501,875. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) opened at 12.10 on Tuesday. The company’s 50 day moving average is $11.07 and its 200-day moving average is $10.50. Spring Bank Pharmaceuticals Inc has a 12 month low of $7.62 and a 12 month high of $13.25. The firm’s market cap is $93.86 million.
Separately, William Blair began coverage on shares of Spring Bank Pharmaceuticals in a report on Friday, August 19th. They set an “outperform” rating and a $26.00 price objective for the company.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/13/spring-bank-pharmaceuticals-inc-sbph-insider-nezam-h-afdhal-acquires-2400-shares.html
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of therapeutics using its small molecule nucleic acid hybrid (SMNH), chemistry platform. Its SMNH compounds are small segments of nucleic acids that the Company designs to selectively target and modulate the activity of specific proteins implicated in various disease states.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Spring Bank Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.